Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Flecainide acetate: critical care administration guidelines.

S Senior1, C Baessler, M Monzo

  • 1Du Pont Critical Care, Inc., Waukegan, Ill.

Heart & Lung : the Journal of Critical Care
|January 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Life expectancy inequalities in Wales before COVID-19: an exploration of current contributions by age and cause of death and changes between 2002 and 2018.

Public health·2021
Same author

Accelerating global vaccination coverage of frontline workers and populations at risk of severe COVID-19 complications.

Public health·2021
Same author

miR-328 mediates a metabolic shift in colon cancer cells by targeting SLC2A1/GLUT1.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2018
Same author

miR-203 and miR-221 regulate SOCS1 and SOCS3 in essential thrombocythemia.

Blood cancer journal·2016
Same author

The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.

Blood cancer journal·2015
Same author

MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia.

Leukemia·2013

Flecainide is effective for treating ventricular arrhythmias due to its convenient dosing and efficacy. However, caution is advised in patients with severe left ventricular dysfunction or pre-existing conduction issues.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Ventricular arrhythmias pose a significant clinical challenge.
  • Effective antiarrhythmic drug therapy is crucial for managing these conditions.

Purpose of the Study:

  • To evaluate the role of flecainide in treating ventricular arrhythmias.
  • To assess flecainide's efficacy and safety profile across different patient populations.

Main Methods:

  • The study reviewed existing data on flecainide's use in ventricular arrhythmia treatment.
  • Patient outcomes were analyzed based on left ventricular function and presence of conduction system disease.

Main Results:

  • Flecainide demonstrated high efficacy in controlling ventricular ectopic activity.

Related Experiment Videos

  • The drug showed promise in stable patients with normal or mildly reduced left ventricular function.
  • Concerns were noted for patients with severe left ventricular dysfunction or pre-existing conduction disease.

    • Conclusions:

    • Flecainide offers a valuable treatment option for ventricular arrhythmias, particularly in select patient groups.
    • Careful patient selection is essential to maximize benefits and minimize risks associated with flecainide therapy.